Adoptive cell transfer as personalized immunotherapy for human cancer

By S. Rosenberg, N. Restifo. Science, 2015

2,295 citations recorded by the source corpus.

Adoptive cell therapy (ACT) is a highly personalized cancer therapy that involves administration to the cancer-bearing host of immune cells with direct anticancer activity. ACT using naturally occurring tumor-reactive lymphocytes has mediated durable, complete regressions in patients with melanoma, probably by targeting somatic mutations exclusive to each cancer. These results have expanded the reach of ACT to the treatment of common epithelial cancers. In addition, the ability to genetically engineer lymphocytes to express conventional T cell receptors or chimeric antigen receptors has further extended the successful application of ACT for cancer treatment.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/8cf7bc8f76d522c0153a68b7699952ec6c9b03a2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

Current Challenges in Cancer Treatment. (2016, background): “Early experiences in acute lymphoblastic leukemia have shown encouraging clinical efficacy results that merit further study in larger trials and other solid tumors.(37,38)”
Intratumoral Tcf1+PD‐1+CD8+ T Cells with Stem‐like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy (2019, positive): “In addition, tumor-derived T cells expanded in vitro can mediate therapeutic responses after adoptive transfer (Rosenberg and Restifo, 2015), indicating that tumor-reactive T cells are not completely differentiated or that a subset of these cells is less differentiated (Speiser et al.”
Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids (2018, positive): “Traditionally, ex vivo systems to analyze T cell-tumor interaction have to a very large extent focused on cutaneous melanoma, both because of the availability of robust approaches to expand tumor-infiltrating T cells for this disease (Rosenberg and Restifo, 2015), and because of the relative ease wi”
A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations (2018, background): “One such therapy utilizes in vitro-activated, autologous CTLs to selectively target tumor cells (7).”